Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Summary
Pharmaceutical company Amgen announced that combining its medication with an immunotherapy treatment from AstraZeneca substantially lowers the mortality risk for individuals suffering from a severe type of lung cancer. This combined drug approach aims to extend the overall survival time for affected patients.
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.